Evidence map›Paper›PMID 40659819›Full record

ArticleScientific reports2025

Long-term benefits of TUDCA supplement in ARSACS zebrafish model.

Valentina Naef, Stefania Della Vecchia, Michela Giacich, Rosario Licitra, Tiziana Bachetti, Gabriela Coronel Vargas, Marco Ponassi, Filippo Maria Santorelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valentina NaefNeurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, 56128, Pisa, Italy. valentina.naef@gmail.com.
Stefania Della VecchiaNeurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, 56128, Pisa, Italy.
Michela GiacichNeurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, 56128, Pisa, Italy.
Rosario LicitraDepartment of Veterinary Sciences, University of Pisa, 56124, Pisa, Italy.
Tiziana BachettiIRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Gabriela Coronel VargasIRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Marco PonassiIRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Filippo Maria SantorelliNeurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, 56128, Pisa, Italy. filippo3364@gmail.com.

Funding

Fondation de l'Ataxie Charlevoix-Saguenay seed grant 2022Fondazione Telethon GSA21G006Ministero della Salute RC 5X1000
6 · The paper itself

Abstract

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurodevelopmental and neurodegenerative disorder characterized by ataxia, spasticity, and peripheral neuropathy. However, several studies have highlighted that some patients also experience cognitive, emotional and social deficits, suggesting a more complex clinical picture that extends beyond motor symptoms. Building on these findings, this study aimed to: (i) investigate locomotor, social and cognitive deficits in adult sacs

Indexed as

Muscle SpasticitySpinocerebellar AtaxiasTaurochenodeoxycholic AcidAnimalsBehavior, AnimalBrainCircadian RhythmDietary SupplementsDisease Models, AnimalProteomicsSocial BehaviorTranscriptomeZebrafishTaurochenodeoxycholic AcidursodoxicoltaurineARSACSAtaxiaNeurodegenerationTUDCAZebrafish

Identifiers

PMID40659819
PMCPMC12260040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.